Prostate cancer vaccine (Northwest Biotherapeutics)

N/A

Report date: 2022/11/25 17:42:38

Base Information

Drug NameProstate cancer vaccine (Northwest Biotherapeutics)
Drug Alias NameDC1/HRPCDCVax-ProstateCaPVax
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsNeoplasm MetastasisProstatic NeoplasmsPancreatic Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNorthwest Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNorthwest Biotherapeutics IncNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisProstatic NeoplasmsPancreatic Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A